Oncology News | pharmaphorum

News

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress

News

Merck gets EU approval for Keytruda in triple-negative breas...

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form of the disease.

News

Strike two for Novartis' lung cancer antibody canakinumab

Expectations for Novartis' canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) failed to meet its primary objecti

News

BMS strikes back against Merck in EU oesophageal cancer mark...

Merck & Co's Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment in the EU earlier this year, but will now face competition from B

News

UK startup Leucid raises £11.5m for solid tumour CAR-T thera...

CAR-T therapies have revolutionised the treatment of some blood cancers, but so far haven't been able to repeat that success in solid tumours.

News

Good news for Lilly as sintilimab hits the spot in lung canc...

Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent's sintilimab last year, and a new trial in lung cancer will raise its hopes of

AZ's Imfinzi is first immunotherapy to raise survival in bil...

Merck gets EU approval for Keytruda in triple-negative breas...

Strike two for Novartis' lung cancer antibody canakinumab

BMS strikes back against Merck in EU oesophageal cancer mark...

UK startup Leucid raises £11.5m for solid tumour CAR-T thera...

Good news for Lilly as sintilimab hits the spot in lung canc...

Novo Nordisk preps filings for sickle cell drug etavopivat

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks